346 related articles for article (PubMed ID: 28974047)
1. Heparin Mimetics: Their Therapeutic Potential.
Mohamed S; Coombe DR
Pharmaceuticals (Basel); 2017 Oct; 10(4):. PubMed ID: 28974047
[TBL] [Abstract][Full Text] [Related]
2. Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease.
Voynow JA; Zheng S; Kummarapurugu AB
Front Pharmacol; 2020; 11():1011. PubMed ID: 32733248
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors of protein interaction with glycosaminoglycans (SMIGs), a novel class of bioactive agents with anti-inflammatory properties.
Harris N; Kogan FY; Il'kova G; Juhas S; Lahmy O; Gregor YI; Koppel J; Zhuk R; Gregor P
Biochim Biophys Acta; 2014 Jan; 1840(1):245-54. PubMed ID: 24060749
[TBL] [Abstract][Full Text] [Related]
4. Heparin mimetics with anticoagulant activity.
Nahain AA; Ignjatovic V; Monagle P; Tsanaktsidis J; Ferro V
Med Res Rev; 2018 Sep; 38(5):1582-1613. PubMed ID: 29446104
[TBL] [Abstract][Full Text] [Related]
5. Heparin/heparan sulphate-based drugs.
Gandhi NS; Mancera RL
Drug Discov Today; 2010 Dec; 15(23-24):1058-69. PubMed ID: 20974281
[TBL] [Abstract][Full Text] [Related]
6. Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity.
Lanzi C; Cassinelli G
Molecules; 2018 Nov; 23(11):. PubMed ID: 30413079
[TBL] [Abstract][Full Text] [Related]
7. Heparin, Heparan Sulphate and Sepsis: Potential New Options for Treatment.
Hogwood J; Gray E; Mulloy B
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259415
[TBL] [Abstract][Full Text] [Related]
8. Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-D-glucuronidase (heparanase).
Gandhi NS; Freeman C; Parish CR; Mancera RL
Glycobiology; 2012 Jan; 22(1):35-55. PubMed ID: 21746763
[TBL] [Abstract][Full Text] [Related]
9. Heparin mimetics.
Coombe DR; Kett WC
Handb Exp Pharmacol; 2012; (207):361-83. PubMed ID: 22566233
[TBL] [Abstract][Full Text] [Related]
10. Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties.
Avci FY; Karst NA; Linhardt RJ
Curr Pharm Des; 2003; 9(28):2323-35. PubMed ID: 14529394
[TBL] [Abstract][Full Text] [Related]
11. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
Hoppensteadt D; Walenga JM; Fareed J; Bick RL
Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
[TBL] [Abstract][Full Text] [Related]
12. Heparin affin regulatory peptide modulates the endogenous anticoagulant activity of heparin and heparan sulphate mimetics.
Mejdoubi-Charef N; Courty J; Sineriz F; Papy-Garcia D; Charef S
Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):296-302. PubMed ID: 22672269
[TBL] [Abstract][Full Text] [Related]
13. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis.
Ferro V; Dredge K; Liu L; Hammond E; Bytheway I; Li C; Johnstone K; Karoli T; Davis K; Copeman E; Gautam A
Semin Thromb Hemost; 2007 Jul; 33(5):557-68. PubMed ID: 17629854
[TBL] [Abstract][Full Text] [Related]
14. The Role of Heparan Sulfate in Inflammation, and the Development of Biomimetics as Anti-Inflammatory Strategies.
Farrugia BL; Lord MS; Melrose J; Whitelock JM
J Histochem Cytochem; 2018 Apr; 66(4):321-336. PubMed ID: 29290153
[TBL] [Abstract][Full Text] [Related]
15. Heparin mimetics as potential intervention for COVID-19 and their bio-manufacturing.
Jiang L; Zhang T; Lu H; Li S; Lv K; Tuffour A; Zhang L; Ding K; Li JP; Li H; Liu X
Synth Syst Biotechnol; 2023 Mar; 8(1):11-19. PubMed ID: 36313216
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Detection of BODIPY-, Biotin-, and
Spijkers-Shaw S; Devlin R; Shields NJ; Feng X; Peck T; Lenihan-Geels G; Davis C; Young SL; La Flamme AC; Zubkova OV
Angew Chem Int Ed Engl; 2024 Mar; 63(13):e202316791. PubMed ID: 38308859
[TBL] [Abstract][Full Text] [Related]
17. Glycosaminoglycans and Glycosaminoglycan Mimetics in Cancer and Inflammation.
Morla S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013618
[TBL] [Abstract][Full Text] [Related]
18. Current trends in the development of anticoagulant and antithrombotic drugs.
Fareed J; Hoppensteadt D; Walenga JM; Bick RL
Med Clin North Am; 1994 May; 78(3):713-31. PubMed ID: 8170266
[TBL] [Abstract][Full Text] [Related]
19. Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds.
Mohan CD; Hari S; Preetham HD; Rangappa S; Barash U; Ilan N; Nayak SC; Gupta VK; Basappa ; Vlodavsky I; Rangappa KS
iScience; 2019 May; 15():360-390. PubMed ID: 31103854
[TBL] [Abstract][Full Text] [Related]
20. Study of physico-chemical properties of novel highly sulfated, aromatic, mimetics of heparin and heparan sulfate.
Liang A; Thakkar JN; Desai UR
J Pharm Sci; 2010 Mar; 99(3):1207-16. PubMed ID: 19711446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
